Replies to post #143859 on Biotech Values

[ciotera]

not aware of any examples of this (coformulation)

I think it happens all the time and I don't see why FTC would get involved. Will FTC get involved when GILD coformulates GS-7977 which they acquired via Pharmasset with their own in-house NS5a?

If ABT got away with coformulating lopinavir and ritonavir and then raising the price of stand-alone ritonavir five-fold to drive the PI business toward Kaletra, I think Roche has little to worry about here.

[genisi]

I wonder if that would raise the FTC's hackles?

Probably.